Neuroepithelioma  >>  sonolisib (PX 866)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sonolisib (PX 866) / Pfizer
NCT01616199: Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma

Checkmark PX-866 + vemurafenib in BRAF-mutant malignant melanoma
Oct 2013 - Aug 2013: PX-866 + vemurafenib in BRAF-mutant malignant melanoma
Terminated
1/2
24
US
PX-866, PI-3K inhibitor, vemurafenib, Zelboraf
Cascadian Therapeutics Inc.
Advanced BRAF-mutant Cancers
12/14
03/15

Download Options